Introduction
PCa will account for about one-quarter of new cancer diagnoses in men in 2015, with 202 800 estimated new cases and will be the second most common cause of cancerrelated deaths in the United States with 27 540 estimated deaths [1] . Many patients with no evidence of metastatic disease undergo treatment for cure with surgery or radiation. Unfortunately, many of these patients develop a recurrence and ultimately succumb to their disease. Understanding how, when, and why these patients developed disseminated disease remains a high priority for the field.
Cancer can theoretically metastasize to almost every organ of the body and these metastases play a central role in most cancer-related deaths. Tumor cells mainly travel to distant sites through the blood. Important steps in haematogenous metastasis in solid tumors include migration and invasion of those cells from the primary tumor into the blood vessels, circulation in the bloodstream (circulating tumor cells), dissemination to distant sites (disseminated tumor cells), and extravasation and eventual colonization in metastatic niches/sites [2 ] (Graph 1).
Circulating tumor cells
As early as 1869, Asworth noted that cancer cells could be found in circulating blood [3] . Although this was almost 150 years ago, the identity and role of circulating tumor cells (CTCs) in cancer metastasis remains unclear. Over the last decade, research on developing CTCs as minimally invasive multifunctional biomarkers has become the 'Holy Grail' of the cancer community. The detection, capture, and characterization of CTC's in peripheral blood as a 'real-time liquid biopsy' continues to be developed as an alternative to standard biopsies. A benefit of the liquid biopsy is the fact that it can be conducted repeatedly with low risk for side effects, monitoring cancer progression and response to therapy [3,4 ,5]. 
Prostate cancer metastasis
PCa cells mainly metastasize to bone sites. The majority of men with clinically localized PCa who develop these bone metastases do so many years after the resection of the primary tumor. This demonstrates a delay between the initial treatment and the biochemical recurrence (BCR), the first sign of future overt metastasis -suggesting that cancer cells escaped early in the disease (prior to surgery or radiation) and are able to stay dormant in the bone marrow for years before switching to a proliferative phenotype and eventually causing metastatic progression [7, 8] 
Different types of cancer dormancy
There are many theories to explain how DTCs are kept in a dormant state before they emerge as a clinically evident metastasis. Cancer dormancy may be divided physiologically into 'cellular dormancy' or 'tumor mass dormancy'. The latter can be subdivided into 'angiogenic' and 'immunologic' dormancy. It is increasingly appreciated that the microenvironment has an important role in conferring and maintaining these states [10,11 ] 'Cellular dormancy' is a state in which individual cells are quiescent and halted in the G0 phase of the cell cycle. One of the major causes for cancer cells to enter this type of dormancy appears to be hypoxia of the microenvironment. Dormant cells can re-enter the cell cycle (and thus exit the G0 arrest) and resume proliferation when the circumstances are favorable, for instance with the addition of growth factors, cytokines and nutrients. The second mechanism, 'angiogenic dormancy', is caused by the lack of angiogenesis, and thereby nutrients, which prevent cancer cells from proliferating. The tumor mass is kept constant and at a limited size, due to a balance between proliferation and apoptosis of cells. The third mechanism which can cause dormancy is 'immune surveillance', where the immune system keeps a proliferating tumor mass limited to a constant size via persistent cytotoxic activity; that is, 'immune-mediated dormancy' [9 ,11
,12] ( Figure 1 ).
An important property of dormant DTCs as opposed to senescent DTCs is the fact that they retain the capability to proliferate, but that they are by definition currently not dividing. This is determined by the lack of proliferating markers (for example Ki-67) when DTCs are profiled at the single-cell level. This makes them resistant to chemotherapies targeting cell division [13, 14] . Multiple other factors in different studies are suggested to contribute to the development of chemotherapy resistance in PCa patients; that is, ABCG2 activation, inhibition of apoptosis, overexpression of P-glycoprotein and multidrug resistance gene 1, and mutational alterations in the tubulin gene [15] . A recent study by Hao et al. demonstrated in a preclinical model the role of both CD44 and CD147 in the enhancement of metastatic capacity and chemoresistance of PCa cells. They propose that selective targeting both factors alone or combined with docetaxel may limit PCa metastasis and increase chemosensitivity [16] .
The haematopoietic stem cells niche The result of these factors is that those 'niche-engaged' PCa cells are more resistant to therapeutic intervention, either by becoming quiescent or through other protective mechanisms of the bone marrow environment [17 ,18] . Factors known to drive and maintain haematopoietic stem cell (HSC) quiescence (for example, CXCR4, stem cell factor-1 (SDF-1) and angiopoietin 1 (ANG1)) may also act on DTCs in the bone marrow [19] . PCa cells express CXCR4, a member of the seven-transmembrane G-protein-coupled chemokine receptors. The stromal cells in the HSC niche, in particular the osteoblasts secrete SDF-1, the ligand for CXCR4. The migration of cancer cells and the adhesion to niche cells are regulated by the interactions between A study by Taichman et al. showed earlier that the HSC niche in the BM was able to promote cellular tumor dormancy. They demonstrated that prostate cancer cell lines express the growth-arrest specific 6 receptors (GAS-6, derived from osteoblasts) Axl, Tyro3 and Mer. In vivo studies showed that when Axl levels predominate, the prostate cancer cells became growth arrested and remained quiescent (in response to GAS-6), compared to the PCa cells that express a low Axl/tyro ratio, which were able to escape from dormancy. This study showed a possible association of the expression ratio of Axl and Tyro3, with the ability of PCa cells to switch between a dormant and proliferative phenotype in the metastasis process [22 ,23] .
Different cell intrinsic factors and signals from the microenvironment (secreted as part of their normal activity) are associated with an alteration of the molecular and cellular pathways of the DTCs, which can result in a switch between a dormant and proliferative phenotype [24 ] . For example, endothelial-derived thrombospondin 1 (TSP1), bone morphogenic protein 7 (BMP7), transforming growth factor-b2 (TGF-b2) and growth arrestspecific 6 (GAS6) can mediate DTC quiescence in bone marrow. BMP7 is a TGF-b family member and is secreted by bone marrow stromal cells. This protein is capable of inducing inhibition of ERK and p38 activation that can induce dormancy in PCa tumor cells [12, 25 ] . Bragoda et al. demonstrated in a head and neck squamous cell carcinoma model that stromal cells in the BM can produce TGF-b1, which can upregulate the p38/ERK ratio in DTCs, which then remain dormant. To induce cell growth arrest, TGF-b2-induced dormancy was required; this was achieved by TGF-b receptor 1, TGF-b receptor III and SMAD1/5 activation. Systemic inhibition of TGFb receptor 1 or p38 activates dormant DTCs, which lead to metastasis [26] . In addition, a recent patient-derived xenograft (PDX) model, showed in vitro that cellular adhesion of prostate cancer cells with each other and with BM stroma activates the cells to proliferate and promotes them to escape from dormancy. Furthermore, global gene expression showed a downregulation of TGFb2 in the PCa PDX lines when proliferating, compared to the cells that were not proliferating; thus this could be a possible mechanism for PCa cells to escape from dormancy as well [27] .
In a study about the formation of bone metastatic lesions in breast cancer (BCa) patients, an important role has been found for VCAM-1, a cell adhesion molecule that recruits osteoclast progenitors and elevates the local osteoclast activity. They showed in a bone metastatis dormancy model that the expression of VCAM-1 promoted a metastatic outgrowth in the bone in breast cancer cell lines [28] . Although PCa bone metastases are mostly caused by osteoblastic activity, a study of Morrisey et al. showed a subset of PCa bone metastases samples obtained from rapid autopsy, a variety in osteolytic activity. Since osteoblastic and osteoclastic activities are often coupled, this suggests that there may be an important role of VCAM-1 for the prevention and inhibition of metastatic recurrence in the bone of PCa patients [29] (Figure 1 ).
Detection of circulating and disseminated tumor cells
Many different assays have been developed for the detection of CTCs in whole blood samples, including microfluidic chips and methods based on size-exclusion, red blood cell lysis, and density separation. A novel method that does not rely on any single protein strategy is the Epic CTC platform. With this method, all nucleated cells are retained as a blood smear on 'sticky' slides and stained with fluorescent antibodies, for example, against cytokeratins, CD45 and DAPI, and subsequently imaged with a high definition scanner. An advantage of this system is the capability to analyze multiple parameters for the characterization of CTCs without enrichment [30] . Another novel non-invasive method to monitor CTCs and tumor evolution over time, based on density separation, is the Rarecyte system which also saves nucleated cells on positively charged slides for analysis [31 ] .
The only FDA-approved assay for CTC detection in patients with metastatic breast, prostate and colon cancer is the Cellsearch system; an immunomagnetic system for the enumeration of circulating tumor cells of epithelial origin. It defines a CTC according to its size, lack of the leukocyte maker CD45, and positivity for EpCAM and CK. The enrichment of CTCs is achieved by using immunomagnetic antibodies against EpCAM [4 ,5,32,33] .
There are no FDA-approved assays to detect DTCs, which make it difficult to standardize detection of PCa DTCs as the field attempts to determine the significance of disseminated cells at the time of primary therapy [34] . CTC systems are being adapted to isolate and detect DTCs in the BM [24 ] . Another technique used for the detection of DTCs is the reverse transcriptase polymerase chain reaction (RT-PCR) to detect PSA. For this technique there is no enrichment required, due to high reaction sensitivity. Disadvantages of this technique include lack of 'seeing' the DTCs (not allowing for characterization) and the fact that some PCa DTCs do not express PSA (with the result that the presence of DTCs could be underestimated) [9 ] .
Strategies to treat dormant disseminated tumor cells
Given the recent data about DTCs and their role in formation of metastases, the question arises whether it would be better to target these DTCs while they are still dormant. There are theoretical strategies to 'treat' dormant DTCs. One idea is the 'chronic dormancy maintenance therapy' to keep the dormant tumor cells quiescent. Another strategy is the use of 'niche-targeted agents' to sensitize the DTCs to cytotoxic treatment, thereby killing the dormant DTCs. Either strategy could result in metastasis prevention (Figure 2 ).
Chronic dormancy maintenance therapy
This treatment strategy could be achieved by the chronic activation of several pathways which drive tumor cells in a dormant state (i.e. P38) or by the use of small molecules that mediate DTC quiescence (i.e. TSP1) [35] . Possible drawbacks of keeping DTCs dormant include long-term effects of chronic systemic induction of these factors on physiologic processes in the body. TSP1 has, for example, anti-angiogenic potential besides its anti-tumor function [18] . Moreover, when supplementing niche-derived factors, it is still possible that dormant DTC may eventually switch to a proliferative phenotype; so this type of treatment will may give the patient a feeling of false security. Current strategies for chronic dormancy maintenance are only in preclinical testing. A recent clinical trial by Banys et al. in patients with breast cancer showed that zoledronic acid (an inhibitor of osteoclast-mediated bone resorption) is able to contribute to DTC eradication in the bone marrow. They propose that the positive influence of the bisphosphonates on survival in the adjuvant setting may be due to their effects on DTCs. More research is needed to answer the question whether zoledronic acid really has impact on DTCs in PCa patients and if this treatment can maybe prevent these patients for developing metastasis [36] .
Conclusions and future perspectives
Much remains to be learned in the fields of CTCs, DTCs, and cancer cell dormancy. In vitro models and standardized methods to detect and isolate CTCs and DTCs are needed. It appears that many autocrine and paracrine signals are needed to induce a proliferative switch in dormant prostate cancer DTCs. Potential treatment strategies are in development to target dormant DTCs or their environment, with the aim to keep them dormant or to eradicate them from the BM. Since which patient will eventually develop metastatic disease cannot be currently predicted, it is difficult to determine which patients will receive a benefit from targeting dormant cancer cells. Future research must be done to determine if all earlystage patients with detected DTCs in the BM, but with no other signs of disease, should be treated. 
